Novo Nordisk A/S buy mnake
Summary
This prediction ended on 11.11.16 with a price of €30.87. The price of Novo Nordisk A/S has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -25.23%. mnake has 50% into this predictionNovo Nordisk is a Danish pharmaceutical company that specializes in diabetes care and research. It is considered to be one of the largest companies in the world that focus exclusively on diabetes management, with a product portfolio that ranges from insulin treatment to obesity management. The company is listed on the Copenhagen Stock Exchange and has gained global recognition for its commitment to sustainable business practices and its contribution to diabetes research and treatment. Novo Nordisk has a strong financial track record and has consistently delivered solid returns to investors over the years.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Novo Nordisk A/S | - | - | - | - |
iShares Core DAX® | -0.612% | 0.567% | 12.585% | 14.838% |
iShares Nasdaq 100 | -3.018% | -3.205% | 26.208% | 38.328% |
iShares Nikkei 225® | -2.647% | 0.330% | 9.482% | 5.652% |
iShares S&P 500 | -1.932% | -1.126% | 23.191% | 38.791% |
Comments by mnake for this prediction
In the thread Novo Nordisk A/S diskutieren
übertrieben
Novo Nordisk wurde nach Zahlen und Aussichten wohl zu sehr verprügelt, durchaus kann es noch unter 40 Euro gehen, dann werden aber die Käufer massiv zuschlagen, es bleibt volatil, aber mittelfristig sehe ich klar Potential. Was sonst bei meiner Lieblangsaktie ?